©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessHypogonadism, female hypergonadotropic; differential diagnosis expanded

Summary

Short information

Comprehensively expanded differential diagnostic panel for Hypogonadism, female hypergonadotropic containing 16 and altogether 49 curated genes

The FSHR polymorphism p.Asn680Ser may be relevant with regard to dose calculation prior to ovarian stimulation and is therefore reported if explicitly requested. doi: 10.1007/s00129-021-04785-6

ID
HP9855
Number of genes
33 Accredited laboratory test
Examined sequence length
32,8 kb (Core-/Core-canditate-Genes)
60,5 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

NGS +

[Sanger]

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
BMP151179NM_005448.2XL
CYP17A11527NM_000102.4AR
CYP19A11512NM_031226.3AR
EIF2B52166NM_003907.3AR
FIGLA660NM_001004311.3AD
FOXL21131NM_023067.4AD
FSHR2088NM_000145.4AR
GALT1140NM_000155.4AR
HFM14308NM_001017975.6AR
MCM82523NM_032485.6AR
MCM93432NM_017696.3AR
MSH42811NM_002440.4AR
NOBOX2076NM_001080413.3AD
NR5A11386NM_004959.5AD, AR
SOHLH11164NM_001101677.2AR
STAG33678NM_012447.4AR
AIRE1638NM_000383.4AD, AR
BUB1B3153NM_001211.6AD
C14orf391890NM_174978.3AR
DIAPH23306NM_006729.5XL
EIF2B21056NM_014239.4AR
EIF2B41569NM_015636.4AR
FMR11899NM_002024.6XL
GDF91365NM_005260.6AD, AR
MSH52505NM_002441.5AR
NANOS3593NM_001098622.3AD
NOG699NM_005450.6AD
NUP1072778NM_020401.4AR
PGRMC1588NM_006667.5XLR
POF1B1770NM_024921.4XLR
POU5F11083NM_002701.6AD
PSMC3IP654NM_016556.4AR
SYCE11109NM_001143763.2AR

Informations about the disease

Clinical Comment

Hypergonadotropic hypogonadism is characterized by low levels of sex hormones and increased gonadotropins in females with a 46XX karyotype. In girls, puberty is delayed, and in initially inconspicuous women hypergonadotropic hypogonadism leads to primary ovarian insufficiency (POI), which is defined by development before age 40 resembling menopause. In addition to infertility, women with POI are at increased risk for a number of comorbidities, including osteoporosis as well as increased cardiovascular morbidity and mortality. The genetic disorders rarely include (a late diagnosed) 45X Turner syndrome, more commonly pre-mutations in the Fragile X Mental Retardation Type 1 (FMR1) gene in up to 15% of cases, but also monogenic syndromic or non-syndromic disorders. Two thirds of these cases remain primarily unexplained, although idiopathic hypergonadotropic hypogonadism may be associated with mutations in a variety of different genes. Using NGS approaches genetic alterations may be detected in up to 25% of cases with female hypergonadotropic hypogonadism. Therefore, a negative molecular genetic finding excludes by no means the clinical diagnosis.

References: doi: 10.1007/s12020-021-02626-z

doi: 10.1210/jendso/bvz037.

The FSHR polymorphism p.Asn680Ser may be relevant with regard to dose calculation prior to ovarian stimulation and is therefore reported if explicitly requested. doi: 10.1007/s00129-021-04785-6

 

Synonyms
  • Allelic: 17,20-lyase deficiency, isolated (CYP17A1)
  • Allelic: 46XX sex reversal 4 (NR5A1)
  • Allelic: 46XY sex reversal 3 (NR5A1)
  • Allelic: Acromesomelic dysplasia 3 (BMPR1B)
  • Allelic: Adrenocortical insufficiency (NR5A1)
  • Allelic: Aromatase excess syndrome (CYP19A1)
  • Allelic: Blepharophimosis, epicanthus inversus + ptosis, type 1 (FOXL2)
  • Allelic: Blepharophimosis, epicanthus inversus + ptosis, type 2 (FOXL2)
  • Allelic: Brachydactyly, type A1, D (BMPR1B)
  • Allelic: Brachydactyly, type A2 (BMPR1B)
  • Allelic: Brachydactyly, type B2 (NOG)
  • Allelic: Colorectal cancer, somatic (BUB1B)
  • Allelic: D-bifunctional protein deficiency (HSD17B4)
  • Allelic: Fragile X syndrome (FMR1)
  • Allelic: Fragile X tremor/ataxia syndrome (FMR1)
  • Allelic: Galloway-Mowat syndrome 7 (NUP107)
  • Allelic: Hydrops, lactic acidosis + sideroblastic anemia (LARS2)
  • Allelic: Leukoencephalopathy with vanishing white matter (EIF2B2, EIF2B4, EIF2B5)
  • Allelic: Mitochondrial DNA depletion syndrome 7, hepatocerebral type (TWNK)
  • Allelic: Mosaic variegated aneuploidy syndrome 1 (BUB1B)
  • Allelic: Multiple synostoses syndrome 1 (NOG)
  • Allelic: Nephrotic syndrome, type 11 (NUP107)
  • Allelic: Non-obstructive azoospermia [panelapp] (MSH4)
  • Allelic: Premature chromatid separation trait (BUB1B)
  • Allelic: Progressive external ophthalmoplegia with mitochondrial DNA deletions, AD 3 (TWNK)
  • Allelic: Spermatogenic failure 15 (SYCE1)
  • Allelic: Spermatogenic failure 32 (SOHLH1)
  • Allelic: Spermatogenic failure 52 (C14orf39)
  • Allelic: Spermatogenic failure 8 (NR5A1)
  • Allelic: Stapes ankylosis with broad thumbs + toes (NOG)
  • Allelic: Symphalangism, proximal, 1A (NOG)
  • Allelic: Tarsal-carpal coalition syndrome (NOG)
  • 17-alpha-hydroxylase/17,20-lyase deficiency (CYP17A1)
  • Aromatase deficiency (CYP19A1)
  • Autoimmune polyendocrinopathy syndrome type I, with/-out reversible metaphyseal dysplasia (AIRE)
  • Combined oxidative phosphorylation deficiency 8 (AARS2)
  • Galactosemia (GALT)
  • Hypogonadotropic hypogonadism 24 without anosmia (FSHB)
  • Leukoencephalopathy, progressive, with ovarian failure (AARS2)
  • Ovarian dysgenesis 1 (FSHR)
  • Ovarian dysgenesis 2 (BMP15)
  • Ovarian dysgenesis 3 (PSMC3IP)
  • Ovarian dysgenesis 4 (MCM9)
  • Ovarian dysgenesis 5 (SOHLH1)
  • Ovarian dysgenesis 6 (NUP107)
  • Ovarian hyperstimulation syndrome (FSHR)
  • Ovarian response to FSH stimulation (FSHR)
  • Ovarioleukodystrophy (EIF2B2, EIF2B4, EIF2B5)
  • Perrault syndrome (SGO2)
  • Perrault syndrome 1 (HSD17B4)
  • Perrault syndrome 2 (HARS2)
  • Perrault syndrome 3 (CLPP)
  • Perrault syndrome 4 (LARS2)
  • Perrault syndrome 5 (TWNK)
  • Premature Ovarian Insufficiency [panelapp] (BMPR1B)
  • Premature ovarian failure 1 (FMR1))
  • Premature ovarian failure 10 (MCM8)
  • Premature ovarian failure 12 (SYCE1)
  • Premature ovarian failure 13 (MSH5)
  • Premature ovarian failure 14 (GDF9)
  • Premature ovarian failure 18 (C14orf39)
  • Premature ovarian failure 2A (DIAPH2)
  • Premature ovarian failure 2B (POF1B)
  • Premature ovarian failure 3 (FOXL2)
  • Premature ovarian failure 4 (BMP15)
  • Premature ovarian failure 5 (NOBOX)
  • Premature ovarian failure 6 (FIGLA)
  • Premature ovarian failure 7 (NR5A1)
  • Premature ovarian failure 8 (STAG3)
  • Premature ovarian failure 9 (HFM1)
  • Premature ovarian failure [panelapp] (BUB1B)
  • Premature ovarian failure [panelapp] (DACH2)
  • Premature ovarian failure [panelapp] (EIF4ENIF1)
  • Premature ovarian failure [panelapp] (KHDRBS1)
  • Premature ovarian failure [panelapp] (POLR2C)
  • Premature ovarian failure [panelapp] (POLR3H)
  • Premature ovarian failure [panelapp] (SYCP2L)
  • Premature ovarian insufficiency [panelapp] (PGRMC1)
  • Primary ovarian failure (MONDO:0005387] (MSH4)
  • Primary ovarian insufficiency (MSH4)
  • Primary ovarian insufficiency [panelapp] (NANOS3)
  • Primary ovarian insufficiency [panelapp] (NOG)
Heredity, heredity patterns etc.
  • AD
  • AR
  • XL
  • XLR
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

No text defined